I want to thank the writer for highlighting about the cost of an upcoming important oral treatment of hepatitis C.
ISLAMABAD: This is with reference to the article “Costly cure for hepatitis C” (January 3). I want to thank the writer for highlighting this important issue about the cost of an upcoming important oral treatment of hepatitis C.
Among the several options which can be used to overcome price barriers, patent opposition is an important step and we have already seen this happening in India. If Gilead, the company that has come up with the treatment for hepatitis C, would get patents on Sofosbuvir — the treatment in question — in Pakistan, then it would be very difficult to negotiate a reasonable price and poor patients in Pakistan will not be able to benefit from this treatment.
Aziz ur Rehman
Published in The Express Tribune, January 4th, 2014.
Like Opinion & Editorial on Facebook, follow @ETOpEd on Twitter to receive all updates on all our daily pieces.
